STAAR Surgical approves USD 50 million buyback for STAAR Surgical stock

Published on 10/01/2026 at 12:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 93.53 million, up 111.10 percent year over year. STAAR Surgical stock has a consensus USD 28.45 target.

STAA, US8577001096, Illustration mit AI erstellt.

STAAR Surgical (ISIN US8577001096) authorized a USD 50.00 million share repurchase program on September 24, 2026, according to STAAR Surgical. The authorization can run for twelve months and covers open-market purchases, privately negotiated transactions and other permitted methods.

Buyback meets stronger results

The capital-allocation move followed a sharp improvement in the second quarter of 2026. MarketBeat reported quarterly revenue of USD 93.53 million, up 111.10 percent from the same period a year earlier, while earnings per share reached USD 0.39 against a USD 0.22 consensus estimate.

The repurchase authorization permits STAAR to reacquire up to 5.20 percent of outstanding shares. The company said in its September 24 release that purchases will be funded through organic free cash flow and cash on hand.

Analysts raise targets selectively

Stifel Nicolaus upgraded STAAR Surgical from Hold to Buy on September 29, 2026, and raised its price target from USD 28.00 to USD 31.00, according to MarketBeat. The same overview listed four Buy, six Hold and three Sell ratings, producing a consensus Hold rating and a USD 28.45 target.

The analyst split remains important because other target changes have been less constructive. MarketBeat said Jefferies cut its target from USD 28.00 to USD 23.00 on September 22, 2026, while Wedbush reduced its target from USD 40.00 to USD 37.00 in August.

Balance sheet supports flexibility

STAAR reported USD 181.5 million in cash, cash equivalents and investments available for sale as of July 3, 2026, in the company release. That liquidity gives the buyback a measurable balance-sheet anchor, although the authorization does not require STAAR to repurchase a specific number of shares.

STAAR develops implantable Collamer lenses for vision correction and sells its EVO ICL product line in more than 85 countries. The company also reported that more than 4 million ICL lenses had been sold by September 24, 2026, linking the repurchase decision to a business built around a global ophthalmic product platform.

Stock range remains wide

STAAR Surgical last traded at USD 22.61 on Nasdaq on September 30, 2026 at 4:00 p.m. ET. Its market capitalization was USD 1.1 billion, and its 52-week range was USD 15.59 to USD 35.87 on the same date.